<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688077</url>
  </required_header>
  <id_info>
    <org_study_id>LTC-524/030408</org_study_id>
    <nct_id>NCT00688077</nct_id>
  </id_info>
  <brief_title>FGF-23 Suppressibility by Calcitonin</brief_title>
  <official_title>Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <brief_summary>
    <textblock>
      Introduction:

      Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an
      FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important
      regulator of FGF-23 production and secretion in healthy humans.

      Aim:

      In this study we wish to examine the FGF-23 suppressive effects of calcitonin in healthy men.

      Study Design:

      placebo-controlled, cross-over study

      Method:

        -  All twelve subjects are examined on two occasions, once after exposure to placebo 1 ml
           NaCl 0.9% subcutaneously, and once following calcitonin 200 IU/ml subcutaneously

        -  On both occasions frequent bloodsampling will take place, out an indwelling catheter in
           de forearm vein.

        -  Sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes

        -  Mealtimes: Calcium and Phosphate intake standardized on both occasions

        -  All samples are analyzed for FGF-23, using a C-terminal FGF-23 ELISA kit (Immunotopics,
           San Clemente, USA) that measures intact and C-terminal fragments of FGF-23, and one that
           measures only intact FGF-23

        -  Samples obtained at T-15, T0, T240 and T480 are stored for later analysis of Ca,
           albumin, PO4, PTH, 25-OHD and 1,25-OHD

      Endpoint:

      A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of
      calcitonin 200 IU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.</measure>
    <time_frame>eight hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0,9% 2 ml, single subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin</intervention_name>
    <description>Calcitonin 200 IU/ml, single subcutaneous injection, experimental group</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCl 0,9 % 1ml, single subcutaneous injection, placebo group</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2.

        Exclusion Criteria:

          -  Serum creatinin &gt;100 mmol/L, or glomerular filtration rate &lt;80 ml/min.

          -  Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels.

          -  Any medication.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <name_title>H. de Boer MD. PhD.</name_title>
    <organization>Rijnstate Hospital, Arnhem</organization>
  </responsible_party>
  <keyword>Fibroblast growth factor - 23</keyword>
  <keyword>Calcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

